日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma

贝伐单抗治疗复发性和难治性脑膜瘤的多机构 II 期临床试验

Priya Kumthekar, Sean Aaron Grimm, Roxanne T Aleman, Marc C Chamberlain, David Schiff, Patrick Y Wen, Fabio Massaiti Iwamoto, Demirkan Besim Gursel, David A Reardon, Benjamin Purow, Masha Kocherginski, Irene Helenowski, Jeffrey J Raizer

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

每月一次帕瑞肽 LAR(SOM230C)治疗复发性或进行性脑膜瘤的 II 期研究

Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Wong, Jan Drappatz, Glenn J Lesser, Sam Haidar, Rameen Beroukhim, Eudocia Q Lee, Lisa Doherty, Debra Lafrankie, Sarah C Gaffey, Mary Ger

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

一项评估 AMG 102(利妥木单抗)治疗复发性胶质母细胞瘤患者的疗效和安全性的 II 期研究

Patrick Y Wen, David Schiff, Timothy F Cloughesy, Jeffrey J Raizer, John Laterra, Melanie Smitt, Michael Wolf, Kelly S Oliner, Abraham Anderson, Min Zhu, Elwyn Loh, David A Reardon